Biologics License Application (BLA)
The formal submission a manufacturer files with the U.S. FDA to obtain approval to market a biologic product, demonstrating its safety, purity, and potency. Approval of a BLA is required before a biologic can be sold.
What is a Biologics License Application (BLA)?
A Biologics License Application (BLA) is the formal submission a manufacturer files with the U.S. Food and Drug Administration to seek approval to market a biologic product. It compiles the evidence intended to show that the product is safe, pure, and potent.
The application brings together data on manufacturing, quality, and clinical study results for the FDA's review. It is the regulatory pathway specific to biologic products, paralleling the application route used for conventional drugs.
Why is a BLA important?
Approval of a Biologics License Application (BLA) is required before a biologic can be legally sold and used in the United States. Without it, the product cannot reach the market, so the BLA is a decisive milestone in a biologic's path from development to availability.
The review process gives regulators a structured way to evaluate safety, quality, and effectiveness before patients are exposed to the product. This gatekeeping role makes the BLA central to how new biologic therapies are brought to market.
- what is a bla
- biologics license application
- bla fda
- bla meaning
- bla vs nda
- biologics license application definition